Table 5. Stratification analysis between the genotypes of SNP2 rs1800470 polymorphism and CWP risk.

Variables	Case/control	Case [n(%)]		Control [n(%)]		P	OR (95% CI)	Adjusted OR(95% CI)a
		TT/CT	CC	TT/CT	CC
Total	508/526	461(90.75)	47(9.25)	441(83.84)	85 (16.16)	0.012	0.53(0.36-0.77)	0.54(0.37-0.79)
Exposure period(y)
<28	221/223	199(90.04)	22(9.96)	185(82.96)	38(17.04)	0.032	0.54(0.31-0.94)	0.54(0.31-0.95)
≥28	287/303	262(91.29)	25(8.71)	256(84.49)	56(15.51)	0.034	0.52(0.31-0.87)	0.56(0.32-0.96)
Smoking status
Never	289/324	265(91.70)	24(8.30)	264(81.48)	60(18.52)	0.003	0.40(0.24-0.66)	0.40(0.24-0.66)
Ever	219/202	196(89.50)	23(10.50)	177(87.62)	25(12.38)	0.713	0.83(0.46-1.52)	0.89(0.48-1.67)
Stage
I	237/526	211(89.03)	26(10.97)	441(83.84)	85(16.16)	0.230	0.91(0.56-1.16)	0.80(0.56-1.15)
II	216/526	200(96.59)	16(7.41)	441(83.84)	85(16.16)	0.004	0.42(0.24-0.73)	0.41(0.22-0.76)
III	55/526	50(90.91)	5(9.09)	441(83.84)	85(16.16)	0.172	0.52(0.20-1.34)	0.50(0.18-1.36)

^a Adjusted for age, smoking and exposure period.